UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g)
OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS
UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS
UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number 001-11397
VALEANT PHARMACEUTICALS INTERNATIONAL
One Enterprise
Aliso Viejo, California 92656
(949) 461-6000
Aliso Viejo, California 92656
(949) 461-6000
registrant’s principal executive offices)
8.375% Senior Notes due 2016
None
(Titles of all other classes of securities for which a duty to file reports
under section 13(a) or 15(d) remains)
under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1) | o | |
Rule 12g-4(a)(2) | o | |
Rule 12h-3(b)(1)(i) | þ | |
Rule 12h-3(b)(1)(ii) | o | |
Rule 15d-6 | o |
Approximate number of holders of record as of the certification or notice date: none
Pursuant to the requirements of the Securities Exchange Act of 1934, Valeant Pharmaceuticals International has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
October 27, 2010 | By: | /s/ Robert Chai-Onn | ||
Robert Chai-Onn | ||||
Executive Vice President, General Counsel and Corporate Secretary | ||||